Crisaborole

Generic Name
Crisaborole
Brand Names
Eucrisa
Drug Type
Small Molecule
Chemical Formula
C14H10BNO3
CAS Number
906673-24-3
Unique Ingredient Identifier
Q2R47HGR7P
Background

Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
...

Indication

Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.

Associated Conditions
Mild Atopic dermatitis, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis

Phase 3
Withdrawn
Conditions
Atopic Dermatitis
Interventions
Other: JW-100
Drug: Eucrisa
First Posted Date
2021-08-23
Last Posted Date
2022-12-19
Lead Sponsor
Applied Biology, Inc.
Registration Number
NCT05016284
Locations
🇧🇷

Centro Universitário Nilton Lins, Manaus, Amazonas, Brazil

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Phase 4
Completed
Conditions
Atopic Dermatitis
Eczema
Interventions
Drug: Crisaborole
First Posted Date
2019-07-17
Last Posted Date
2022-07-19
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Target Recruit Count
30
Registration Number
NCT04023084
Locations
🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Steroid-reducing Effects of Crisaborole

First Posted Date
2019-02-06
Last Posted Date
2024-07-19
Lead Sponsor
Johns Hopkins University
Target Recruit Count
24
Registration Number
NCT03832010
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

First Posted Date
2018-12-10
Last Posted Date
2023-10-13
Lead Sponsor
Northwestern University
Target Recruit Count
23
Registration Number
NCT03770858
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

First Posted Date
2018-08-24
Last Posted Date
2022-10-31
Lead Sponsor
University of Rochester
Target Recruit Count
92
Registration Number
NCT03645057
Locations
🇺🇸

University of Rochester Dermatology, Rochester, New York, United States

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Phase 4
Completed
Conditions
Seborrheic Dermatitis
Interventions
Drug: Crisaborole
First Posted Date
2018-06-26
Last Posted Date
2021-10-29
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
30
Registration Number
NCT03567980
Locations
🇺🇸

Dermatology at the Whitaker Clinic, Birmingham, Alabama, United States

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Phase 2
Completed
Conditions
Morphea
Interventions
Drug: Crisaborole
First Posted Date
2017-11-22
Last Posted Date
2021-04-01
Lead Sponsor
Duke University
Target Recruit Count
8
Registration Number
NCT03351114
Locations
🇺🇸

Duke University, Durham, North Carolina, United States

Eucrisa for Atopic Dermatitis

First Posted Date
2017-08-16
Last Posted Date
2024-08-27
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
28
Registration Number
NCT03250663
Locations
🇺🇸

Wake Forest University Heath Sciences, Winston-Salem, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy